Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX26 in advanced solid tumors and lymphomas
NCT05078593Phase 1Completed
- Sponsor
- Henlius
- Start
- Oct 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hlx26 in solid tumor and lymphoma, sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Oct 2021; status: completed.
02
Drugs
hlx26
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT05078593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078593.